Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: CD44, CD24 and ALDH1 are the most consistently used biomarkers to identify and characterise the breast cancer stem cell (CSC) phenotype. However, most studies performed until now analysed samples of invasive ductal carcinomas of no special type (IDC-NST). Therefore, prevalence and clinical significance of these CSC markers in breast carcinomas of special histological types (SHT) is largely unknown. For that reason, this study aims to determine the distribution of the breast CD44, CD24 and ALDH1 CSC markers among a series of invasive breast carcinomas of SHT, in comparison with a series of IDC-NST.

Methods: 117 invasive SHT breast carcinomas were analysed for the expression of CD44, CD24 and ALDH1, by immuhohistochemistry. The distribution of these CSC markers was evaluated among the distinct histological special types, and the results were compared with a series of 466 IDC-NST.

Results: The expression prevalence of the breast CSC markers differed between special types and IDC-NST. Medullary, papillary and tubular carcinomas were enriched in the CSC phenotype CD44(+)/CD24(-/low) (80.0%, 100.0% and 100.0%, respectively, vs 45.3% in IDC-NST). Considering the ALDH1 cytoplasmic tumour expression, only medullary and metaplastic carcinomas displayed significant increase in CD44(+)/CD24(-/low)/ALDH1(+) CSC phenotype frequency (36.4% and 28.6%, respectively, vs 4.8% in IDC-NST).

Conclusions: The expression distribution of breast CSC markers is largely dependent on histological type. Interestingly, within the distinct SHT, medullary and metaplastic carcinomas are the two types highly associated with high-grade carcinomas, basal-like and claudin-low molecular subtypes, and to the CSC phenotype CD44(+)/CD24(-/low)/ALDH1(+).

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2012-201169DOI Listing

Publication Analysis

Top Keywords

csc markers
20
cd44 cd24
16
cd24 aldh1
16
csc phenotype
16
breast carcinomas
12
csc
9
cancer stem
8
breast
8
breast cancer
8
special histological
8

Similar Publications

Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer.

Biochim Biophys Acta Rev Cancer

September 2025

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford, United Kingdom. Electronic address:

Cancer stem cells (CSCs) are central to tumour initiation, progression, and relapse, yet their dynamic and adaptive nature hampers therapeutic targeting. Once viewed as a fixed subpopulation, CSCs are now recognised as a fluid functional state that tumour cells can enter or exit, driven by intrinsic programs, epigenetic reprogramming, and microenvironmental cues. This plasticity complicates identification due to inconsistent marker expression and enables resistance, dormancy, and metastasis.

View Article and Find Full Text PDF

FASN promotes the stemness of cancer stem cells and protects colorectal cancer cells from ferroptosis by inhibiting the activation of SREBP2.

Front Immunol

September 2025

Department of Gastroenterology, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese Peoples Liberation Army (PLA) General Hospital, Beijing, China.

Introduction: Fatty acid synthase (FASN) is a key regulator of lipid metabolism, but its role in colorectal cancer (CRC) stemness and ferroptosis remains unclear.

Methods: FASN expression in CRC was analyzed using TCGA data and validated in CRC cell lines (CACO-2, HCT116, SW480) and normal HIEC-6 cells via qRT-PCR and Western blot. HCT116 cells (highest FASN expression) were used for experiments.

View Article and Find Full Text PDF

Background: Cerebrospinal fluid (CSF) serves an essential role in biomarker research. New Parkinson's disease (PD) classifications incorporate CSF α-synuclein status into trial design. This study evaluated the safety and feasibility of serial CSF collection in participants enrolled in the Parkinson's Progression Markers Initiative (PPMI).

View Article and Find Full Text PDF

A synergy of CD133 overexpression and TGF-β supplementation in tumorigenesis of ovarian cancer cell lines in a three-dimensional sphere forming model.

Cell Immunol

August 2025

School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Electronic address:

Background: Ovarian cancer (OC) is a highly lethal gynecological malignancy, mainly due to chemoresistance and tumor recurrence. Cancer stem cells (CSCs) may be responsible for chemoresistance, and CSC has become a new target for treatment. In this study, we aimed to develop a three-dimensional (3D) OC model with well-recapitulated stemness in the tumor microenvironment (TME).

View Article and Find Full Text PDF

Background: Therapeutic resistance in oral cancer, with cancer stem cells (CSCs) playing a pivotal role, remains a major clinical challenge. CD44, a key CSC marker, has been implicated in multidrug resistance mechanisms through drug efflux, DNA repair, and anti-apoptotic pathways. This meta-analysis aims to systematically evaluate the association between CD44 expression and clinicopathological characteristics in oral cancer patients through analysis of controlled clinical studies.

View Article and Find Full Text PDF